3.95
+0.07(+1.80%)
Currency In USD
Address
3891 Ranchero Drive
Ann Arbor, MI 48108
United States of America
Phone
734 887 3903
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
304
First IPO Date
June 26, 2013
| Name | Title | Pay | Year Born |
| Sheldon L. Koenig | President, Chief Executive Officer & Director | 1.26M | 1966 |
| Benjamin O. Looker | General Counsel & Corporate Secretary | 696,350 | 1982 |
| Benjamin Halladay | Chief Financial Officer | 713,958 | 1986 |
| John Harlow | Chief Commercial Officer | 718,859 | 1975 |
| Stephen Pinkosky | Vice President of Drug Discovery of Early Pre-Clinical Development | 0 | N/A |
| LeAnne Bloedon | VP & Head of Development | 0 | N/A |
| Glenn Brame | Chief Technical Operations Officer | 0 | 1957 |
| Betty Jean Swartz | Chief Business Officer | 0 | N/A |
| Tiffany Aldrich | Associate Director of Corporate Communications | 0 | N/A |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.